A Trial to Assess the Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With PLD

NCT05281328 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

71

Enrollment

INDUSTRY

Sponsor class

Conditions

Polycystic Liver Disease

Interventions

DRUG: CAM2029
DRUG: Placebo

Sponsor

Camurus AB